Introduction

Sarcoidosis is a multisystem granulomatous disease of unknown etiology that has a wide range of clinical manifestations. The histopathology of the disease is characterized by the presence of noncaseating granulomas that can appear in any organ but are most commonly located in the lungs and lymph nodes.

The normal course of the disease is highly variable and difficult to predict, and cases can range from being asymptomatic to displaying a progressive course that leads to pulmonary fibrosis. Despite advances in imaging technology and the analysis of immune and inflammatory processes that occur in sarcoidosis, prognostic factors that allow disease severity to be determined at diagnosis are lacking.

remain to be identified. The usefulness of Siltzbach’s radiographic classification of sarcoidosis as an indicator of disease activity or prognosis has not been clearly demonstrated. Furthermore, although bronchoalveolar lavage (BAL) is used systematically for the diagnosis of sarcoidosis, studies aimed at evaluating the usefulness of BAL cell counts as predictors of disease course have yielded inconclusive results.

The aim of this study was to determine whether BAL fluid exhibits a characteristic cell profile according to radiographic stage in pulmonary sarcoidosis and to determine whether cell analysis provides information about disease course at 12-month follow-up.

Patients and Methods

Subjects and Study Protocol

The study group consisted of 34 patients diagnosed with sarcoidosis that had not been treated with corticosteroids. Diagnosis of the disease was confirmed by histology in patients with compatible clinical and radiographic manifestations. Fiberoptic bronchoscopy with transbronchial biopsy and BAL was performed in all patients. Other causes of granulomatous inflammation were excluded by microbiological analysis of BAL fluid for the presence of fungi and mycobacteria. In patients with a negative transbronchial biopsy, pathologic diagnosis was obtained by lung biopsy, mediastinoscopy, lymph node biopsy, or biopsy of cutaneous lesions.

The following data were collected at diagnosis: age, sex, smoking habit, radiographic stage, results of symptoms questionnaire, respiratory function, serum concentration of angiotensin-converting enzyme (ACE), calcium levels, calciuria at 24 hours, and BAL cell counts.

Four radiographic stages were recognized at diagnosis based on the classification described by Siltzbach: stage 0 (no thoracic involvement), stage I (bilateral hilar lymphadenopathy), stage II (bilateral hilar lymphadenopathy and lung infiltrates), and stage III (lung infiltrates without lymphadenopathy).

At 12-month follow-up, disease course was evaluated by assessment of functional and radiographic change. The criteria of Hunninghake et al. were used to assess deterioration of respiratory function. A reduction of at least 15% compared with initial values was considered significant for forced vital capacity (FVC) and forced expiratory volume in the first second (FEV), a reduction of at least 10% of the initial value was considered significant for total lung capacity (TLC) and diffusion capacity for carbon monoxide corrected for alveolar volume (DLCOc/VA).

Results of Hunninghake et al. were used to assess deterioration of functional and radiographic change. The criteria for radiographic worsening were defined as follows: a) disappearance or improvement of the radiographic findings; b) stabilization, defined as the absence of radiographic change; and c) worsening of the disease, defined as deterioration of the radiographic findings. Following evaluation of radiographic and functional evolution of the disease at 12-month follow-up, the patients were divided into 3 groups: group A (cured or improved), group B (stable), and group C (deteriorated).

Treatment with corticosteroids was initiated based on clinical criteria.

Study Variables

Symptoms questionnaire. Information was collected on the following respiratory symptoms: cough, expectoration, wheezing, and dyspnea. The level of dyspnea was determined according to the Medical Research Council dyspnea scale.

Respiratory function testing and radiography. FVC and FEV were obtained by spirometry and the results used to calculate the FEV/FVC ratio. TLC was determined using body plethysmography (Master Lab, Erich Jaeger, Wurzburg, Germany). DLCOc/VA was obtained via the single breath method. Lung function testing was performed according to the recommendations of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). The results were expressed as percentages of the predicted value. Arterial blood gas analysis was performed at rest breathing room air. High-resolution computed tomography of the thorax was performed in all patients at the beginning of the study and at 12-month follow-up to assess radiographic change.

Blood and urinary parameters. The serum concentrations of ACE and calcium were determined. The concentration of calcium in urine was obtained at 24 hours.

Bronchoalveolar lavage. In accordance with SEPAR guidelines on the use of BAL, 120 to 200 mL of 0.9% saline was instilled in the lingula or mediastinal lobe in 20 to 50 mL aliquots. The total cell count was determined using a Neubauer chamber and the differential cell count using modified May-Giemsa-Grünwald stain (Diff-Quick). Immunophenotype analysis was performed in cryopreserved samples using the avidin-biotin-peroxidase method with monoclonal antibodies against CD4 and CD8 (Dako Cytomation, Barcelona, Spain). The following values were considered to be elevated: more than 15% lymphocytes, more than 3% neutrophils, more than 1% eosinophils, and a CD4/CD8 cell ratio greater than 1.5. These values were established based on a multicenter study performed in healthy subjects.

Lymphocyte subpopulations (CD4 and CD8) were only analyzed in patients who had a proportion of lymphocytes in BAL fluid of more than 15%.

Statistical Analysis

Since the variables did not obey a normal distribution, results were expressed as the median and interquartile range. Differences between radiographic stages and groups were assessed using the χ² test for qualitative variables and the Kruskal-Wallis test for quantitative variables. Correlations were assessed using the Spearman correlation coefficient. Statistical analyses were performed using the SPSS program (SPSS version 12.0, Chicago, IL, USA) and statistical significance was established a P≤.05.

Results

Noteworthy general characteristics were a predominance of women (55.9%), a mean age of 44 years, and a percentage of smokers of 52.9% (Table 1). Histologic confirmation of the diagnosis was obtained for all patients: 24 through transbronchial biopsy, 2 by mediastinoscopy, 6 by lung biopsy, 1 by lymph node biopsy, and 1 by biopsy of a cutaneous lesion.
The most common symptoms were respiratory, particularly cough (60%) and dyspnea (48%). Four patients had cutaneous manifestations: 3 with erythema nodosum and 1 with lupus pernio. One patient displayed confusional syndrome as a result of hypercalcemia but was successfully treated. Over the course of the 12-month follow-up, no patients displayed other extrathoracic manifestations that could influence the course of the disease.

The median baseline values for FVC, FEV₁, TLC, DLCOc/VA, and PaO₂ were all within a normal range. The results of BAL cell analysis are shown in Table 1. These results were within the normal range in 3 patients. Nonsmokers had higher proportions of total lymphocytes and CD4 lymphocytes, and a higher CD4/CD8 cell ratio in BAL fluid than smokers; however, the differences did not achieve statistical significance. No other differences were found in BAL variables.

The serum concentration of ACE was increased in 93% of patients. Comparison of ACE concentrations with BAL variables revealed a moderate correlation with the proportion of lymphocytes (r=-0.45; P=0.03) and neutrophils (r=-0.42; P=0.04).

Corticosteroid treatment was indicated in 26 patients (76.4%), 2 patients received bronchodilator treatment for symptoms of bronchial hyperreactivity, and 6 patients received no treatment. The mean (SD) duration of corticosteroid treatment was 10.7 (2.8) months.

### Radiographic Stages

The following distribution of radiographic stages was observed at diagnosis: 4 patients (11.7%) in stage I, 22 patients (64.7%) in stage II, and 8 patients (23.6%) in stage III.

No statistically significant differences were found between different radiographic stages for age or smoking habit (Table 1), or for lung function (FVC, FEV₁, FEV₁/FVC, TLC, DLCOc/VA, or PaO₂). Serum concentrations of ACE (Table 1) and calcium were higher in patients in radiographic stage II, while calciuria was higher in patients in stage III; these differences did not achieve statistical significance. Although BAL characteristics were not significantly different between radiographic stages, a higher percentage of lymphocytes was found in stage I than in other stages (Table 1).

### Radiographic and Functional Evolution

At 12-month follow-up, 58.8% of patients were considered to be cured (group A) and 8.8% had deteriorated (group C). Remission or cure of the disease was observed in 75% of patients in stage I, 63.6% of patients in stage II, and 37.5% of patients in stage III (Table 2). No statistically significant differences were found between the three groups in terms of age, sex, or smoking habit; however, the percentage of smokers in group C was higher than in the remaining groups (Table 3). Lung function parameters were within a normal range except in group C, in which slight hypoxemia and a reduced FEV₁/FVC ratio were observed; these differences were not statistically significant. Although no statistically significant differences in BAL cell

### TABLE 1

General Characteristics and Analysis of Bronchoalveolar Lavage Fluid in the Total Population and According to Radiographic Stage*

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total (n=34)</th>
<th>Stage I (n=4)</th>
<th>Stage II (n=22)</th>
<th>Stage III (n=8)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>41 (31-52)</td>
<td>33 (28-40)</td>
<td>44 (30-63)</td>
<td>44 (35-52)</td>
<td>.82*</td>
</tr>
<tr>
<td>Sex, % women</td>
<td>55.9</td>
<td>50</td>
<td>54.5</td>
<td>62.5</td>
<td>.89*</td>
</tr>
<tr>
<td>Smokers, %</td>
<td>52.9</td>
<td>25</td>
<td>54.5</td>
<td>62.5</td>
<td>.45*</td>
</tr>
<tr>
<td>ACE, U/mL</td>
<td>60 (30-100)</td>
<td>58 (30-86)</td>
<td>79 (38-104)</td>
<td>43 (20-68)</td>
<td>.22*</td>
</tr>
<tr>
<td>Bronchoalveolar lavage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages, %</td>
<td>55 (44-71)</td>
<td>49 (41-63)</td>
<td>57 (40-77)</td>
<td>54 (49-62)</td>
<td>.79*</td>
</tr>
<tr>
<td>Lymphocytes, %</td>
<td>35 (24-50)</td>
<td>48 (33-38)</td>
<td>35 (17-51)</td>
<td>33 (30-48)</td>
<td>.49*</td>
</tr>
<tr>
<td>Neutrophils, %</td>
<td>1 (0-3)</td>
<td>2 (1-4)</td>
<td>1 (0-2)</td>
<td>4 (1-7)</td>
<td>.15*</td>
</tr>
<tr>
<td>Eosinophils, %</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>1 (0-4)</td>
<td>.11*</td>
</tr>
<tr>
<td>CD4, % of total lymphocytes</td>
<td>63 (47-82)</td>
<td>59 (13-79)</td>
<td>63 (48-86)</td>
<td>63 (48-74)</td>
<td>.65*</td>
</tr>
<tr>
<td>CD8, % of total lymphocytes</td>
<td>26 (15-34)</td>
<td>22 (9-30)</td>
<td>21 (14-37)</td>
<td>30 (20-42)</td>
<td>.55*</td>
</tr>
<tr>
<td>CD4/CD8 ratio cell</td>
<td>2 (1-6)</td>
<td>3 (0-11)</td>
<td>3 (1-6)</td>
<td>2 (2-4)</td>
<td>.80*</td>
</tr>
</tbody>
</table>

*Data are shown as medians (interquartile range). ACE indicates angiotensin-converting enzyme.

†Bilateral hilar lymphadenopathy.

‡Bilateral hilar lymphadenopathy and lung infiltrates.

§Lung infiltrates without lymphadenopathy.

||Kruskal-Wallis test.

¶χ² test.

### TABLE 2

Radiographic Stage at Diagnosis and Radiographic/Functional Evolution at 12-Month Follow-up

<table>
<thead>
<tr>
<th>Groups*</th>
<th>Stages†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I</td>
</tr>
<tr>
<td>A (n=20)</td>
<td>3</td>
</tr>
<tr>
<td>B (n=11)</td>
<td>1</td>
</tr>
<tr>
<td>C (n=3)</td>
<td>0</td>
</tr>
</tbody>
</table>

*A indicates cured or improved; B, stable; C, deteriorated.

†I indicates bilateral hilar lymphadenopathy; II, bilateral hilar lymphadenopathy and lung infiltrates; III, lung infiltrates without lymphadenopathy.
counts were observed between the groups, the percentage of lymphocytes was higher in group A. Lymphocyte subpopulations were analyzed in 22 patients (15 from group A, 6 from group B, and 1 from group C). No statistically significant differences were observed between groups A and B (Table 3). Although the serum concentration of ACE tended to be higher in group A (\( P = .07 \)) and the concentrations of calcium in serum and urine were slightly higher in group B, these differences were not statistically significant.

Corticosteroid treatment was administered in 14 patients (70%) from group A, 9 (81.8%) from group B, and 3 (100%) from group C. No statistically significant differences in disease course were observed between patients who received corticosteroid treatment and those who did not (\( P = .32 \)). A similar result was obtained when the results were analyzed according to radiographic stage at presentation (stage I, \( P = .24 \); stage II, \( P = .75 \); stage III, \( P = .80 \)).

**Discussion**

In the present study, the differential cell count and analysis of lymphocyte subpopulations in BAL fluid did not distinguish radiographic stages at diagnosis of sarcoidosis. Nevertheless, it is noteworthy that the percentage of lymphocytes observed in radiographic stage I was higher than in the other stages. This finding suggests the presence of damage to the lung parenchyma that is revealed by BAL at stages in which radiography does not detect interstitial alterations. The classification of sarcoidosis based on radiographic observations does not appear to be related to the results obtained by cell analysis of BAL fluid. Thus, radiography alone is of limited use in the evaluation of disease activity or as a basis for therapeutic decisions.

The results of BAL cell analysis were normal in 3 patients: 2 patients in stage II and 1 patient in stage III. This indicates that such normal results from BAL cell analysis in a patient with a clinical and radiographic profile highly indicative of sarcoidosis do not exclude the possibility that the disease is present. A possible explanation for such cases is a predominance of fibrosis with a less apparent inflammatory phase and, consequently, the absence or severe reduction of indicators in BAL fluid.

Given the effect of smoking on cell populations in BAL fluid, the influence of smoking habit on the differential cell count and cell subpopulations was analyzed. Our results did not differ from those obtained in a multicenter study based on a large population of healthy subjects.16

Although at 12-month follow-up a large percentage of patients (91.2%) were either cured or showed improvement, 8.8% displayed disease progression. These findings are consistent with results obtained in other studies and demonstrate that, although sarcoidosis generally has a good prognosis, in 10% to 30% of patients the disease follows a progressive and irreversible course that leads to pulmonary fibrosis.17

Lung function testing revealed a reduction in the FEV/FVC ratio and slight hypoxemia in group C that could be related to the presence of a higher percentage of smokers in this group. Although BAL cell analysis showed a slightly higher percentage of lymphocytes in group A, the differences observed were not statistically significant.
Recent study found that patients showing clinical levels of more than 28% were accompanied by an increased value of BAL cell analysis. Nevertheless, it is possible not allow us to draw conclusions about the prognostic information on disease activity; classification of sarcoidosis has limited practical use.

The discrepancies in reported results appear to be related to methodological differences between studies and the heterogeneity of study populations. The small sample size used in the present study does not allow us to draw conclusions about the prognostic value of BAL cell analysis. Nevertheless, it is possible to make the following observations: a) radiographic classification of sarcoidosis has limited practical use when considered in isolation, since it does not provide information on disease activity; b) although BAL cell counts aid diagnosis and allow the intensity of the pulmonary inflammatory response to be determined, they do not appear to predict disease course over the first 12 months in our patient group. It will be necessary to increase the number of patients in each group to better assess the prognostic value of lymphocyte subpopulation (CD4 and CD8) counts.

In the future, increased understanding of the pathogenesis of pulmonary sarcoidosis may facilitate the identification of new soluble components of BAL fluid that may be used as prognostic markers to aid disease management and the development of new therapeutic strategies.

REFERENCES